Related Experiment Video
Updated: Aug 31, 2025
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Current Status and Trends of Research on Anthracycline-Induced Cardiotoxicity from 2002 to 2021: A Twenty-Year
Yu Wang1, Yifei Rao1, Zhijian Lin1,2
1School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China.
Abstract:
Anthracyclines constitute the cornerstone of numerous chemotherapy regimens for various cancers. However, the clinical application of anthracyclines is significantly limited to their dose-dependent cardiotoxicity. A comprehensive understanding of the current status of anthracycline-induced cardiotoxicity is necessary for in-depth research and optimal clinical protocols. Bibliometric analysis is widely applied in depicting development trends and tracking frontiers of a specific field. The present study is aimed at revealing the status and trends of anthracycline-induced cardiotoxicity during the past two decades by employing bibliometric software including R-bibliometric, VOSviewer, and CiteSpace. A total of 3504 publications concerning anthracycline-induced cardiotoxicity from 2002 to 2021 were collected from the Web of Science Core Collection database. Results showed significant growth in annual yields from 90 records in 2002 to 304 papers in 2021. The United States was the most productive country with the strongest collaboration worldwide in the field. Charles University in the Czech Republic was the institution that contributed the most papers, while 7 of the top 10 productive institutions were from the United States. The United States Department of Health and Human Services and the National Institutes of Health are the two agencies that provide financial support for more than 50% of sponsored publications. The research categories of included publications mainly belong to Oncology and Cardiac Cardiovascular Systems. The Journal of Clinical Oncology had a comprehensive impact on this research field with the highest IF value and many publications. Simunek Tomas from Charles University contributed the most publications, while Lipshultz Steven E. from the State University of New York possessed the highest H-index. In addition, the future research frontiers of anthracycline-induced cardiotoxicity might include early detection, pharmacogenomics, molecular mechanism, and cardiooncology. The present bibliometric analysis may provide a valuable reference for researchers and practitioners in future research directions.
Insights
Anthracycline chemotherapy causes heart damage, limiting its use. This bibliometric analysis of 3504 studies from 2002-2021 reveals research trends and future directions in anthracycline-induced cardiotoxicity.
Area of Science:
- Oncology
- Cardiac Cardiovascular Systems
Background:
- Anthracyclines are vital chemotherapy agents but cause dose-dependent cardiotoxicity, limiting their clinical use.
- Understanding anthracycline-induced cardiotoxicity is crucial for research and clinical practice.
Purpose of the Study:
- To analyze the status and trends of research on anthracycline-induced cardiotoxicity over the past two decades (2002-2021).
- To identify key contributors, institutions, funding agencies, and impactful publications in this field.
- To highlight emerging research frontiers for future investigation.
Main Methods:
- Bibliometric analysis using R-bibliometric, VOSviewer, and CiteSpace software.
- Analysis of 3504 publications on anthracycline-induced cardiotoxicity from the Web of Science Core Collection database (2002-2021).
Main Results:
- Significant growth in annual publications from 90 (2002) to 304 (2021).
- The United States is the most productive country; Charles University (Czech Republic) is the leading institution.
- The Journal of Clinical Oncology has a significant impact; Simunek Tomas and Lipshultz Steven E. are highly cited researchers.
- Key funding agencies include the US Department of Health and Human Services and NIH.
Conclusions:
- Research on anthracycline-induced cardiotoxicity has expanded significantly over the last two decades.
- Future research should focus on early detection, pharmacogenomics, molecular mechanisms, and cardiooncology.
- This bibliometric analysis provides a valuable reference for future research and clinical strategies.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...